Integrated serum metabolomics reveal molecular mechanism of Xietu Hemu prescription on metabolic dysfunction-associated steatotic liver disease-related obesity

Figure 6 Mechanism prediction of Xietu Hemu prescription therapy in obesity hints leptin is the hub-target and the adenosine monophosphate-activated protein kinase signaling pathway might be the core mechanism. A: Intersection results of Xietu Hemu prescription (XHP) putative targets screened from traditional Chinese medicine systems pharmacology (TCMSP) and PubChem, Obesity targets collected from DisGeNET, Genecards, and DurgBank, and RNA sequencing differential genes (|Log2FC| ≥ 2) computed by Dr. Tom platform; B: Protein-protein interaction network of intersecting targets; C and D: Enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) for the 24 intersecting targets; E: Classification of the top 20 KEGG Pathways; F and G: The top GO terms and KEGG pathways about their respective mapping genes; H-N: Assessment of the tightness between XHP and the adenosine monophosphate-activated protein kinase signaling pathway by molecular docking. XHPS: Xietu Hemu prescription-containing serum.